Selective silencing of expanded CAG repeats: Chemically modified siRNA advances RNA-based therapies for polyglutamine diseases

Key Points

• The study aims to explore the effectiveness of chemically modified siRNA in silencing CAG repeats associated with polyglutamine diseases.
• Synthesis of chemically modified siRNA designed to target CAG repeats
• Application of siRNA to cell models of polyglutamine diseases
• Assessment of gene silencing efficiency and toxicity
• Chemically modified siRNA effectively silenced CAG repeats in cell models
• Demonstrated reduced expression of toxic polyglutamine proteins
• Showed minimal off-target effects and low toxicity